Applicant: Brian Andrew Hills et al. Attorney's Docket No.: 13596-004US1 / 01509US

Serial No.: Unassigned Filed: Herewith Page: 2 of 5

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

- 1. (Original) A method of improving the efficiency or reducing deficiency of ultrafiltration in continuous ambulatory peritoneal dialsysis which comprises administering a composition comprising at least one SAPL in powder form or dispersed or dissolved in a physiologically acceptable non-volatile carrier liquid into the peritoneal cavity before commencing CAPD or between CAPD sessions.
- 2. (Original) A method of improving the efficiency or reducing deficiency of ultrafiltration in continuous ambulatory peritoneal dialysis which comprises administering a composition comprising at least one SAPL in powder form or dispersed or dissolved in a physiologically acceptable non-volatile carrier liquid (other than saline) into the dialysis fluid before commencing a CAPD session.
- 3. (Original) Use of at least one SAPL in powder form or dispersed or dissolved in a physiologically acceptable non-volatile carrier liquid (other than saline) to prepare a medicament for reducing improving the efficiency or reducing deficiency of ultrafiltration in continuous ambulatory peritoneal dialysis.
- 4. (Currently Amended) Use or method according to claim1[, 2 or 3] in the SAPL is selected from diacyl phosphatidylcholines (DAPCs), such as dioleyl phosphatidylcholine (DOPC); distearyl phosphatidylcholine (DSPC) and dipalmitoyl phosphatidylcholine (DPPC).

Applicant: Brian Andrew Hills et al. Attorney's Docket No.: 13596-004US1 / 01509US

Serial No.: Unassigned Filed: Herewith Page: 3 of 5

5. (Original) Use or method according to claim 4 in which the SAPL composition further includes a spreading agent such as a phosphatidyl glycerol (PG), phosphatidyl ethanolamine (PE), phosphatidyl serine (PS), phosphatidyl inositol (PI) or chlorestyl palmitate (CP).

- 6. (Currently Amended) Use or method according to claim 1[,2 or 3] in which the SAPL composition is a mixture of phosphatidylcholine (PC) and phosphatidyl glycerol (PG).
- 7. (Original) Use or method according to claim 6 in which the SAPL composition is a mixture of dipalmitoyl phosphatidylcholine (DPPC), or a phosphatidylcholine blend (PC) which is predominantly dipalmitoyl phosphatidylcholine (DPPC), and phosphatidyl glycerol (PG).
- 8. (Currently Amended) Use or method according to any preceding claim 1 in which the carrier is glycerol, propylene glycol, or a polyethylene glycol.
- 9. (Original) Use or method according to claim 8 in which the carrier is propylene glycol.
- 10. (Currently Amended) Use or method according to any preceding claim $\underline{1}$ in which the SAPL/carrier is in the form of a paste.
- 11. (New) Use or method according to claim 2 in the SAPL is selected from diacyl phosphatidylcholines (DAPCs), such as dioleyl phosphatidylcholine (DOPC); distearyl phosphatidylcholine (DSPC) and dipalmitoyl phosphatidylcholine (DPPC).
- 12. (New) Use or method according to claim 3 in the SAPL is selected from diacyl phosphatidylcholines (DAPCs), such as dioleyl phosphatidylcholine (DOPC); distearyl phosphatidylcholine (DSPC) and dipalmitoyl phosphatidylcholine (DPPC).

Applicant: Brian Andrew Hills et al. Attorney's Docket No.: 13596-004US1 / 01509US

Serial No.: Unassigned Filed: Herewith Page: 4 of 5

13. (New) Use or method according to claim 11 in which the SAPL composition further includes a spreading agent such as a phosphatidyl glycerol (PG), phosphatidyl ethanolamine (PE), phosphatidyl serine (PS), phosphatidyl inositol (PI) or chlorestyl palmitate (CP).

- 14. (New) Use or method according to claim 12 in which the SAPL composition further includes a spreading agent such as a phosphatidyl glycerol (PG), phosphatidyl ethanolamine (PE), phosphatidyl serine (PS), phosphatidyl inositol (PI) or chlorestyl palmitate (CP).
- 15. (New) Use or method according to claim 2 in which the SAPL composition is a mixture of phosphatidylcholine (PC) and phosphatidyl glycerol (PG).
- 16. (New) Use or method according to claim 3 in which the SAPL composition is a mixture of phosphatidylcholine (PC) and phosphatidyl glycerol (PG).
- 17. (New) Use or method according to claim 15 in which the SAPL composition is a mixture of dipalmitoyl phosphatidylcholine (DPPC), or a phosphatidylcholine blend (PC) which is predominantly dipalmitoyl phosphatidylcholine (DPPC), and phosphatidyl glycerol (PG).
- 18. (New) Use or method according to claim 16 in which the SAPL composition is a mixture of dipalmitoyl phosphatidylcholine (DPPC), or a phosphatidylcholine blend (PC) which is predominantly dipalmitoyl phosphatidylcholine (DPPC), and phosphatidyl glycerol (PG).
- 19. (New) Use or method according to claim 2 in which the carrier is glycerol, propylene glycol, or a polyethylene glycol.
- 20. (New) Use or method according to claim 3 in which the carrier is glycerol, propylene glycol, or a polyethylene glycol.